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Abstract
Background: Electrochemotherapy (ECT) is a combined treatment in which high
voltage electroporation (EP) pulses are used to facilitate the uptake of a
chemotherapeutic drug into tumor cells, thus increasing antitumor effectiveness of
the drug. The effect of ECT of deep-seated tumors located close to the heart on
functioning of the heart has not been previously investigated. In this study, we
investigate the effects of intra-abdominal ECT of colorectal liver metastases on
functioning of the heart during the early post-operative care period.
Methods: For ECT high voltage EP pulses with amplitudes of up to 3000 V and 30 A were
delivered in synchronization with electrical activity of the heart. Holter electrocardiographic
(ECG) signals were obtained from 10 patients with colorectal liver metastases treated with
ECT. ECG was recorded during the periods of 24 hours before and after the surgical
procedure involving ECT. Four-hour long night-time ECG segments from both periods
exhibiting the highest level of signal stationarity were analyzed and compared. Changes
in several ECG and heart rate variability (HRV) parameters were evaluated.
Results: No major heart rhythm changes (i.e., induction of extrasystoles, ventricular
tachycardia or fibrillation) or pathological morphological changes (i.e., ST segment
changes) indicating myocardial ischemia were found. However, we found several
minor statistically significant but clinically irrelevant changes in HRV parameters after
ECT procedures: a decrease in median values of the mean NN interval, a decrease in
the low-frequency and in the normalized low-frequency component, and an increase
in the normalized high-frequency component.
Conclusions: Only minor effects of intra-abdominal ECT treatment on functioning of
the heart were found. They were expressed as statistically significant but clinically
irrelevant changes in heart rate and long-term HRV parameters and were as such not
life-threatening to the patients. The nature of these changes is such that they can be
attributed to the known effects of the drugs given to the patients in the post-
operative care. Further investigation is still warranted to unambiguously resolve
whether ECT with high voltage EP pulses applied in immediate vicinity of the heart
is responsible for the observed effects.
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Background
Electroporation-based techniques, like electrochemotherapy (ECT), gene electrotrans-
fection and non-thermal irreversible electroporation, are becoming a viable option for
treatment of internal, deep-seated tumors and tissues (e.g., in bones, brain, liver, lung,
prostate, kidney, colon and esophagus). In such cases, surgical, percutaneous or endo-
scopic procedures are used to gain access to the treatment area [1-18]. These advanced
treatment procedures thus provide new possibilities for restoring, correcting or modify-
ing physiological functions but, at the same time, because of their novelty, complexity
and technical specificity, may also introduce new risks to patients. One of potential
new risks is that application of electroporation (EP), i.e. high voltage electric pulses
could interfere with functioning of the heart. In particular, in treatment of deep-seated
tumors, the electric current can propagate through a larger volume of tissue surround-
ing the treated region due to absence of a protective barrier of the skin, relatively large
inter-electrode distances, and high electric conductivity of internal tissues and organs,
which is even further increased due to EP itself [19]. Therefore, an increased probabil-
ity of EP pulses affecting the cardiac muscle and thus potentially causing heart-related
effects exists in ECT treatment of deep-seated tumors located close to the heart (e.g.
in liver, lung or esophagus) with respect to the same treatment applied to cutaneous
or subcutaneous tumors. If the electric field distribution is such that the heart lies in
the reversibly electroporated area, premature action potentials are generated causing
cardiac arrhythmias [8].
During the study of intra-abdominal ECT of colorectal liver metastases at the Institute
of Oncology Ljubljana, Slovenia [5,6] tumors located relatively close to the heart and sur-
rounded with highly conductive tissue were treated with electric pulses with voltage and
current amplitudes of up to 3000 V and 50 A respectively. Pulses were delivered synchro-
nized with the ECG. Needle electrodes were inserted into liver tissue during open surgery
at inter-electrode distances of up to 3 cm. Such conditions lead to increased probability of
interaction of EP pulses with functioning of the heart. Indeed, according to published stu-
dies on non-thermal irreversible EP, where EP pulses with the same characteristics are
applied as in ECT of colorectal liver metastases (although more pulses are used than in
ECT), different effects on functioning of the heart were observed. Minor and major hemo-
dynamic changes were reported, as well as cardiologic changes due to unsynchronized
irreversible EP pulse delivery, such as systolic hypertension, supraventricular tachycardia,
ventricular tachycardia with pressure drops, ventricular fibrillation, ST segment elevation
and changes in T wave morphology [7,8]. In these studies, major cardiologic changes (ven-
tricular arrhythmias) were terminated by defibrillation, whereas minor effects in general
subsided after EP pulse delivery. However, even when delivery of irreversible EP pulses
was synchronized with the absolute refractory period of the heart cycle, minor cardiac
arrhythmias could still be induced [8]. The authors also reported that the ST segment ele-
vation appearing due to myocardial ablation with synchronized irreversible EP pulses gra-
dually disappeared but the situation did not normalize completely during the 45 min
observation period after the treatment. Nevertheless, no myocardial injury was observed
[8]. The use of ECG synchronization during IRE treatment has thus been greatly explored
in the literature and has become a standard for clinical IRE therapy when treating tumors
in close proximity to the heart [7,8,10,20-22].
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During the clinical study on safety and feasibility of ECT of colorectal liver metas-
tases at the Institute of Oncology Ljubljana we experienced no obvious or clinically
relevant immediate or short-term effects of EP pulses on functioning of the heart dur-
ing the treatment itself. Nevertheless, the observations summarized in the previous
paragraph lead to the hypothesis that EP pulse delivery in close vicinity of the heart
even when synchronized with ECG could induce measurable effects on functioning of
the heart that could remain visible several hours after the treatment. The aim of this
study was thus to explore these effects by evaluating changes in ECG during the early
post-operative care of patients within 24 hours after intra-abdominal surgery and ECT
of colorectal liver metastases.
Methods
Patients and the study
The study of changes in ECG of patients during early post-operative care after intra-
abdominal electrochemotherapy (ECT) procedure was part of the prospective pilot
clinical study conducted at the Institute of Oncology in Ljubljana (EudraCT number:
2008-008290-54; ClinicalTrials.gov: NCT01264952). The objective of this study was to
examine safety and feasibility of ECT of colorectal liver metastases [5,6] with
16 patients included in the study.
Ambulatory 9-lead ECG records (I, II, III, aVR, aVL, aVF, V1, V3, V6) of approxi-
mately 24-hours duration were recorded on the day before and after intra-abdominal
ECT procedure. ECG signals were sampled at 200 Hz and acquired using a holter sys-
tem (SpiderView, ELA Medical, France). These ECG signals were used to investigate
changes in functioning of the heart in early post-operative care. Holter recording
before and after ECT was not possible for patients number 1, 2 and 8 and the signals
recorded on patients number 3, 11 and 16 could not be used due to technical reasons.
ECG signals from ten patients were thus included in the analysis. The main character-
istics of these ten patients and their tumors are presented in Table 1; further patients’
details can be found in [6]. The patients recruited in the study had no serious pre-
existing cardiac condition.
Electrochemotherapy procedure
The protocol of the clinical study was described in detail elsewhere [5,6]. Here it is
summarized briefly and with emphasis on details pertinent to the investigation of the
effects of ECT on ECG.
ECT procedures were performed under combined general and thoracic epidural
anesthesia (TEA). Epidural catheter was placed at T8-12 interspaces before anesthesia,
and a test dose of lidocaine (60 mg) was injected. 30 minutes before surgical incision,
all patients received the prophylactic antibiotics cefazolin (2 g) and metronidazole
(500 mg) as a rapid intravenous infusion. The patients received 25-50mg of levobupiva-
caine epidurally during the operation, according to analgesic needs. General anesthesia
was induced with sufentanyl, propofol, and vecuronium, and after tracheal intubation,
maintained with sevoflurane in 40% oxygen-nitrous oxide balance. A bolus of local
anesthetic levobupivacaine (between 10 to 15 mg) was administered epidurally about
five minutes before surgical incision. Additional epidural levobupivacaine and intrave-
nous vecuronium and sufentanyl were administered during the operation as
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Table 1. Main characteristics of the patients, tumors and EP pulse delivery for individual patient and tumor
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a Patient numbers according to Edhemovic et al. [6], where more patients’ details can be found. For patients not included in this study see the explanation in the Methods section.
b The two longest perpendicular tumor diameters were estimated using ultrasound imaging during intra-abdominal surgery.
c The data for voltage and current in tumor M2 in patient No. 15 was corrupted; therefore the total energy applied to the patient was estimated as twice the energy applied to tumor M1 since almost the same



















appropriate. Epidural analgesia (continuous epidural infusion of 0.25% levobupivacaine)
with rate 3-6 mL/hour and with patient controlled analgesia (PCA) demand dose of
4 ml (lock out time 30 minutes) was continued in all patients postoperatively. During
post-operative care, patients also received intravenously opioid analgesic piritramide,
non-opioid analgesic metamizole and antiemetic metoclopramide as required. In the
case of hypotension, an infusion of vasopressor norepinephrine in low dose (range
from 0.01 - 0.2 µg/kg/min) was administered in order to maintain optimal blood pres-
sure. At night, patients received another dose of the analgesic metamizole and the anti-
psychotic haloperidol.
ECT was performed during open surgery that was primarily performed to treat lar-
ger, unresectable or difficult-to-treat liver metastases [6]. To reach the tumors, two
types of needle electrodes were used: individual needle electrodes for variable geometry
positioning (VG1240, IGEA, Italy) with either a 3 or 4 cm long active (conductive) part
and a diameter of 1.2 mm; and electrodes with fixed hexagonal geometry (N-30-HG,
IGEA, Italy) with a 3 cm long active part, an electrode diameter of 0.7 mm and a fixed
distance between the outer electrodes of 1.7 cm. The decision about selection of vari-
able or fixed geometry electrodes depended on the tumor location and size. Four to six
electrodes with variable geometry were used for larger tumors and tumors located deep
inside the liver, whereas the electrodes with fixed hexagonal geometry were used for
tumors located on the liver surface. When electrodes for variable geometry were used,
a patient-specific treatment plan was prepared before the ECT procedure based on
abdominal cross-sectional CT or MRI images. Treatment planning took into account
the size and location of individual tumors and major blood vessels in order to define
the number and geometrical distribution of the electrodes, distances between the elec-
trodes, pairs of electrodes for EP pulse delivery, and voltages of EP pulses for each pair
of the electrodes [2,5,6,23-25]. These procedures were described in detail in [24,25]
and are available at www.visifield.com.
ECT procedure was performed as follows. First, needle electrodes were inserted into
the tumor and the immediate surrounding tissue according to the treatment plan. The
chemotherapeutic drug bleomycin was then administered intravenously in bolus with a
dose of 15 mg/m2. Delivery of EP pulses was started eight minutes after bleomycin
administration. Eight EP pulses of 100 μs duration were delivered for each pair of the
electrodes by the electric pulse generator Cliniporator Vitae (IGEA, Carpi, Italy).
The delivery of EP pulses was synchronized with ECG via AccuSync 42, an external
R wave triggering device (AccuSync, USA). The ECG signal was acquired by the Accu-
Sync 42 independently of the regular ECG monitoring by the anesthesiologist. The
AccuSync 42 detects the R wave of each individual heartbeat early on the ascending
slope of the R wave and provides a trigger to Cliniporator Vitae. Cliniporator Vitae
delivers pulses 50 ms after a valid trigger pulse, thus avoiding the so-called vulnerable
period of the ventricles (the T-wave). Validation of trigger pulses is performed by a
built-in synchronization algorithm.
The exact protocol of EP pulse delivery depended on the type of electrodes (for more
details see also Table 1). In all cases 8 EP pulses with 100 θs duration were delivered
for each electrode pair. Patients number 4, 7, 9, 10 and 15 were treated using electro-
des for variable geometry. EP pulses were delivered in trains of 8 pulses with one EP
pulse per valid trigger pulse. Patient number 13 was also treated using electrodes for
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variable geometry, the pulses however were delivered in subgroups of 4 pulses per valid
trigger pulse at a repetition frequency of 1 kHz and with EP pulse polarity reversal
between the two subgroups. Patients number 6, 12 and 14 were treated using electro-
des with fixed hexagonal geometry. EP pulses were delivered in subgroups of 4 pulses
per valid trigger pulse at a repetition frequency of 5 kHz and with EP pulse polarity
reversal between the two subgroups. For variable electrode geometry the total number
of pulses delivered to a tumor as well as voltage amplitudes depended on the treatment
plan. For fixed electrode geometry on the other hand the total number of pulses (96
pulses per application) as well as the voltage amplitude (730 V) was fixed. See Table 1
for more details.
ECG analysis
Analysis was performed on ECG signals recorded continuously over periods of 24 hours
and was based on comparison of parameters derived from comparable periods before
and after ECT procedure. The night-time interval between 0:00 and 4:00 a.m. was
selected for analysis because activity of patients was found to be minimal during this
period and therefore the corresponding ECG signals were relatively stationary. ECT was
performed during daytime, usually before 12:00 a.m. so the two extracted parts of ECG
signals for every patient were separated by 24 hours.
In order to detect and classify heartbeats, the initial processing of extracted four-
hour long ECG signals was performed using a previously developed algorithm, which
is described in detail elsewhere [26,27]. Briefly, this algorithm is an extended QRS
detector which provides the Q, R and T peak locations and classifies individual heart-
beats as either normal or abnormal (i.e., abnormal ECG shape or heart rhythm). For
proper functioning of this algorithm, an ECG lead with high R wave amplitude and
large dynamics within QRS complex in comparison to other parts of ECG signal are
required. ECG leads I, II and V6 fulfil these requirements and were analyzed for all
patients. For each patient individually, the ECG lead resulting in the highest number of
detected heartbeats and the lowest number of abnormal heartbeats was selected as the
most appropriate for further analysis. The number of ST segments deviating from the
normal level was identified from the selected ECG lead using commercial holter analy-
sis software (SyneScope, ELA Medical, France).
For reliable analysis of heart rate variability (HRV), noise-free 5 min long subseg-
ments with a small number of abnormal heartbeats are required [28,29]. The threshold
value for acceptable proportion of abnormal heartbeats for HRV analysis was initially
chosen to be 1%. Each four-hour long ECG signal was divided into twelve 20-min long
segments and one 5-min subsegment was extracted from each 20-min segment for
HRV analysis. Each 20-min segment was scanned from its beginning for the first
occurrence of a 5-min subsegment with less than 1% of abnormal heartbeats that at
the same time started at least 10 minutes after the end of the 5-min subsegment from
the preceding 20-min segment. A 5-min subsegment fulfilling both requirements was
extracted and used for HRV analysis. If no 5-min subsegment from a given 20-min
segment could be extracted at the 1% threshold value for abnormal heartbeats, the
threshold value was gradually increased in increments of 1% (up to 5%) and the selec-
tion procedure was repeated until a suitable 5-min subsegment was found. The upper
limit of 5% for the percentage of acceptable abnormal heartbeats was adopted from
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[30] where the authors analyzed the effects of editing abnormal heartbeats on calcula-
tion of HRV measures.
The whole procedure thus resulted in twelve selected 5-min segments for each ECG
record that were appropriate for HRV analysis. They were additionally manually
inspected for correctness of R peak detection, location and heartbeat classification and,
if necessary, corrected to assure correct identification and classification of every single
heartbeat. We developed software (using Matlab, MathWorks, USA) with graphical
user interface for easy and rapid screening and checking for correctness of the located
feature points and classification of heartbeats [31]. After screening and editing of R
peak data, the locations of Q and T peaks were also verified (and corrected if neces-
sary) but only for heartbeats classified as normal since the locations of Q and T peaks
of abnormal heartbeats were unreliable and thus inappropriate for the analysis.
Assessment of QT intervals
QT interval is usually defined as the interval between the start of a Q wave and the
end of a T wave within an individual normal heartbeat. However, we used an interval
between the Q peak and the T peak (peak-to-peak QT intervals, denoted as ppQT),
because Q and T peaks are much easier to detect reliably than the start of a Q wave
and the end of a T wave. The corrected ppQT intervals (denoted as ppQTc intervals)
were determined for each heartbeat as the ppQT interval divided by the square root of
the corresponding RR interval, following the common definition of the corrected QT
interval.
Assessment of heart rate variability
Heart rate variability (HRV) analysis deals with fluctuations in RR interval time series
between normal adjacent QRS complexes. Normal QRS complexes are those resulting
from the sinoatrial node depolarization, and the associated RR intervals are frequently
referred to as NN intervals [28]. The RR interval series obtained from regular ambula-
tory ECG recordings are usually not directly suitable for HRV analysis because of
inclusion of abnormal RR intervals, which is known to affect the results of HRV analy-
sis in general and of frequency-domain HRV analysis in particular [28]. Therefore,
additional preprocessing of RR interval series was needed in order to improve reliabil-
ity of HRV analysis.
After manual editing of RR intervals from each selected 5-min subsegment of the
ECG signals in the previous step, 1% or less abnormal heartbeats in each 5-min sub-
segment were required in order to minimize the error in subsequent calculation of
HRV parameters. If this requirement was not met initially for a given subsegment, it
was replaced with a new one, i.e., with the first next 5-min subsegment from the same
20 minutes long segment according to the requirements for selection and extraction of
ECG subsegments as described above.
In the next step the 5-min subsegments were edited using cubic spline interpolation
method to replace abnormal RR intervals with the interpolated RR intervals. This
approach is considered superior to simple deletion of abnormal RR intervals [32]. An
NN interval sequence of only normal RR intervals was thus obtained. The NN interval
sequence was of course an irregularly sampled sequence (sampling intervals not of the
same length). For frequency domain HRV analysis it was converted to a corresponding
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regularly sampled sequence. Cubic spline interpolation method at 1 kHz sampling rate
was used to fit the non-equidistant NN sequence data. The resulting curve was then
downsampled to 4 Hz sampling rate [27]. This equidistantly sampled NN sequence
was finally used for frequency domain HRV analysis.
Following the recommendations in the literature for short-term ECG recordings [28],
several commonly used linear HRV measures in time domain (mean NN, SDNN,
SDSD, RMSSD, pNN50) and frequency domain (LF, nLF, HF, nHF, LF/HF), as well as
nonlinear measures (Poincaré diagram descriptors, SD1, SD2 and SD1/SD2) were cal-
culated from the NN interval sequences for each 5-min segment included in the analy-
sis (for details see Table 2). Linear detrending of NN interval sequences was performed
before calculation of HRV measures except for the mean NN interval and Poincaré
descriptors to remove the low frequency baseline trend component. HRV measures
were calculated for all twelve 5-min segments of each ECG signal. The median value
for each HRV measure was calculated over all patients, separately for ECG signals
recorded before and after ECT procedure. The comparison of these median values was
then used for evaluation of the effects of ECT procedure on functioning of the heart.
All calculations were performed in Matlab using our own tool for ECG and HRV ana-
lysis developed previously [31].
Frequency-domain HRV measures were initially calculated from power density spec-
tra estimated with non-parametric FFT-based Welch’s periodogram method using




mean NN ms Mean of normal-to-normal (NN) intervals
SDNN ms Standard deviation of NN intervals; an estimate of overall HRV
SDSD ms Standard deviation of differences between adjacent NN intervals; an estimate of short-term
HRV; associated with parasympathetic activity
RMSSD ms Square root of the mean of the sum of the squares of differences between adjacent NN
intervals; an estimate of short-term HRV; associated with parasympathetic activity
pNN50 % Number of pairs of adjacent NN intervals differing by more than 50 ms divided by the total
number of all NN intervals
Nonlinear measures
SD1 ms Standard deviation of the Poincaré plot perpendicular to the line-of-identity; the shortest
diameter of the fitted ellipse; an estimate of short-term HRV; associated with
parasympathetic activity
SD2 ms Standard deviation of the Poincaré plot along the line-of-identity; the longest diameter of
the fitted ellipse; an estimate of long-term HRV; associated with sympathetic activity
SD1/SD2 - Ratio of SD1 to SD2; describes the ratio of short-term to long-term HRV; describes the
relationship between parasympathetic and sympathetic activity
Frequency-domain measures
LF ms2 Power in low frequency range (0.04-0.15 Hz); estimate of long-term HRV; reflects both
sympathetic and parasympathetic activity
nLF n.u. Normalized power of LF; LF/(LF+HF)x100; estimate of long-term HRV; reflects both
sympathetic and parasympathetic activity
HF ms2 Power in high frequency range (0.15-0.4 Hz); estimate of short-term HRV; reflects
parasympathetic (vagal) activity
nHF n.u. Normalized power of HF; HF/(LF+HF)x100; estimate of short-term HRV; reflects
parasympathetic activity
LF/HF - Ratio between LF and HF range powers; describes the relationship between sympathetic
and parasympathetic activity, i.e. sympathovagal balance
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Hamming window and with parametric autoregressive model-based method (AR model
of the order 16 with coefficients determined based on Burg method) [28,29]. Since
both approaches resulted in practically indistinguishable results, only the results of
autoregressive model-based calculation of frequency-domain HRV measures are
reported.
Assessment of parameters of EP pulse delivery
The time course of voltage and current during EP pulse delivery was recorded and
stored for further analysis. These records allowed us to determine the number of EP
pulses delivered to each tumor and to calculate the average values of voltage and cur-
rent and the total energy applied to individual tumor and patient. The median value of
voltage and current delivered within each train of eight EP pulses was first calculated.
Then, the median of these median values for all trains of EP pulses delivered to indivi-
dual tumor was used as a measure of the average voltage and current delivered to the
tumor. Where more than one tumor was treated in a patient, the largest average vol-
tage and current values were taken for statistical analysis. The energy applied to indivi-
dual tumors was determined by integrating the power of all EP pulses (i.e. product of
current and voltage) delivered to the tumor. The total energy applied to a patient was
also determined as the sum of energy delivered to all tumors in the patient. Values of
these electrical parameters were intended for assessment of their association with the
significant changes in ECG or HRV parameters (if found).
Statistical analysis
Several statistical comparisons were performed. The median values of number of
abnormal heartbeats, number of deviated ST segments, ppQTc intervals and HRV
measures obtained from 4-hour ECG signals recorded before and after ECT procedure
on individual patients were compared using paired Wilcoxon Signed Rank test. Linear
regression method was used to determine the degree of association between the para-
meters of EP pulses and the ECG and HRV measures for which statistically significant
changes were found. The statistical analysis was performed using SigmaPlot 11.0 pack-
age (Systat Software Inc., USA) and the p value of less than 0.05 was considered as the
indication of statistically significant differences.
Results
No clinically significant adverse effects such as induction of extrasystoles, ventricular
tachycardia or fibrillation) on functioning of the heart in patients due to ECT proce-
dure were observed in the post-operative care. The analysis of ECG signals recorded
before and after ECT procedure showed no increase in appearance of abnormal heart-
beats in ECG signals recorded after ECT even in cases where abnormal heartbeats
were present in ECG signal before ECT (Table 3). No statistically significant difference
in percentage of abnormal heartbeats and in percentage of deviated ST segments was
found comparing periods before and after ECT procedure (p = 0.054 and p = 0.322,
respectively, Table 3).
ECG signals recorded in patients number 6, 9 and 10 contained large amounts of
high-frequency noise either before or after ECT procedure, which rendered a reliable
determination of ppQTc intervals impossible (Table 3). On the remaining seven
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patients, the comparison of median values of ppQTc interval before and after intra-
abdominal ECT indicated no statistically significant difference (p = 0.469, Table 4).
ECG signals from all 10 patients were included in HRV analysis. The Wilcoxon
Signed Rank test showed statistically significant decrease in median values of para-
meters mean NN interval, LF and nLF, and statistically significant increase in median
nHF after intra-abdominal ECT (Table 4). Statistically significant negative linear corre-
lation was found only between changes in the parameter LF and the number of EP
pulses applied during EP pulse delivery (p = 0.026; Table 5).
Discussion
The results of our study indicate that intra-abdominal surgery involving ECT of color-
ectal liver metastases was associated with only minor and clinically irrelevant changes










No. of beats before ECT
procedure
No. of beats after ECT
procedure
N A (%) ST (%) N A (%) ST (%)
4 II / II NN, ppQTc 14317 12 (0.084) 0 (0) 14216 17 (0.119) 0 (0)
5 II / II NN, ppQTc 15722 3 (0.019) 15692 (99.8) 18112 1 (0.006) 14001 (77.3)
6 II / II NN 13975 309 (2.163) 0 (0) 18271 8 (0.044) 0 (0)
7 II / II NN, ppQTc 16873 20 (0.118) 0 (0) 18820 15 (0.080) 2321 (12.3)
9 II / V6 NN 18321 18 (0.098) 6915 (37.7) 26047 9 (0.035) 0 (0)
10 V6 / I NN 14785 70 (0.471) 0 (0) 15202 23 (0.151) 763 (5.02)
12 V6 / V6 NN, ppQTc 18825 42 (0.223) 0 (0) 17764 6 (0.034) 4395 (24.7)
13 II / II NN, ppQTc 13864 6 (0.043) 0 (0) 19405 8 (0.044) 3209 (16.5)
14 V6 / V6 NN, ppQTc 13857 135 (0.965) 10111 (73.0) 16620 0 (0) 7078 (42.6)
15 II / II NN, ppQTc 17461 25 (0.143) 696 (3.99) 26450 39 (0.147) 25188 (95.3)
Summary 158000 640 (0.403) 33414 (21.1) 190907 126 (0.034) 56955 (29.8)
NN: normal-to-normal heartbeat interval; ppQTc: corrected peak-to-peak QT interval; N: number of heartbeats classified
as normal; A: number of heartbeats classified as abnormal; ST: number of heartbeats with ST segment deviation.
Table 4. Median changes in ECG and HRV parameters after ECT
Evaluated parameters Median change Percentile p
25% 75%
mean ppQTc [ms] -5.03 -17.40 2.45 0.469
mean NN [ms] -161.00 -260.66 -25.05 0.020
SDNN [ms] -11.05 -18.09 -3.12 0.131
SDSD [ms] -3.86 -11.26 0.272 0.232
RMSSD [ms] -3.85 -11.24 0.275 0.232
pNN50 [%] -0.18 -1.50 0.00 0.461
SD1 [ms] -2.73 -7.96 0.19 0.232
SD2 [ms] -15.95 -26.43 -3.52 0.065
SD1/SD2 0.01 -0.11 0.12 0.695
LF [ms2] -93.15 -303.13 -30.15 0.049
HF [ms2] -9.93 -49.76 38.86 0.625
nLF [n.u.] -12.56 -16.81 -10.49 0.049
nHF [n.u.] 12.56 10.49 16.81 0.049
LF/HF -1.04 -3.26 -0.90 0.432
Definitions of parameters are given in Table 2. Statistical significance of the change is presented in the right-most
column (Wilcoxon signed rank test).
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in functioning of the heart detected in early post-operative care and as such presented
no life threat for the patients. No major changes in functioning of the heart such as
rhythm changes (i.e., increased induction of abnormal heartbeats, ventricular tachycar-
dia or fibrillation) or pathological morphological changes (e.g., ST segment changes)
that would suggest myocardial ischemia were found in ECG signals.
According to the literature, surgery and anesthesia produce a stress response char-
acterized by increased sympathetic and hormonal activity which may predispose the
patient to arrhythmias [30]. Post-operative arrhythmias are thus quite common and
affect about 7% of patients that underwent major non-cardiothoracic surgery.
Post-operative arrhythmias occur more commonly in older patients, most often in
the first four days after surgery and are frequently associated with other underlying
complications [33-35]. In addition, EP pulses alone delivered to tissue located near
the heart can induce abnormal heartbeats, even if EP pulses are synchronized with
the refractory period of the cardiac cycle [7,8,36]. The cardiotoxicity of bleomycin,
the chemotherapeutic drug used in intra-abdominal ECT, can also provoke changes
in ECG often manifested as an appearance of or an increase in the incidence of pre-
mature atrial contractions, or as appearance of supraventricular tachycardia, sinus
bradycardia or other conduction abnormalities [37]. However, the abnormal heart-
beats caused by bleomycin are of transient nature, occurring during and shortly after
the drug administration, and would be expected to disappear by the night time per-
iod for which the effects of ECT procedure on ECG were evaluated in our study. The
frequency of abnormal heartbeats was not increased after ECT procedure (Table 3),
which suggests that ECT procedure on its own did not induce additional post-
operative arrhythmias.
EP pulses delivered in immediate vicinity of the heart could potentially cause struc-
tural changes in myocardium and consequently induce myocardial ischemia. The myo-
cardial ischemia can be detected by analysis of changes in ST segment level, by blood
test of values of biomarkers of myocardial necrosis (such as cTn, CK-MB) and by car-
diac imaging [38]. Minor or early stage of myocardial ischemia can be detected with
blood tests, whereas major or late stage myocardial ischemia can be detected also from
ECG. Changes in ST segment level were clearly documented after cardioversion and
defibrillation [39-45], and were recognized to be a transient phenomenon (lasting
between a few seconds to 24 hours) and not associated with structural changes of
myocardium. Our results show no statistically significant change in proportion of
heartbeats with changes in ST segment level in ECG signals recorded after ECT proce-
dure. We can thus conclude that ECT procedure had no effects resulting in ST seg-
ment changes that would suggest the presence of major myocardial ischemia. In the












Δ mean NN 0.919 0.399 0.210 0.154
Δ LF 0.026 0.315 0.522 0.953
Δ nLF 0.239 0.616 0.271 0.060
Δ nHF 0.239 0.616 0.271 0.060
Correlation was evaluated for ECG and HRV parameters with statistically significant change after ECT from Table 4.
Values of p (statistical significance of the correlation) are given in the table.
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future blood tests of cardiac biomarkers could be included in evaluations to investigate
potential early stage myocardial ischemia caused by EP pulses.
Heart rate variability (HRV) analysis is a method for studying the physiological
mechanisms responsible for the control of heart rate, in which the autonomic nervous
system appears to play the primary role. HRV measures strongly depend on conditions
under which ECG signals are recorded and are affected by numerous physiological fac-
tors modulating the normal rhythm of the heart (such as age and gender of the patient,
blood pressure, drugs taken, presence of heart diseases, diabetes, renal failure, surgical
procedure, pain, stress, smoking, alcohol consumption, exercise and sleep) [28,29,46].
When HRV measures are derived from stable ECG signals recorded under controlled,
resting conditions, it is suggested that HRV measures are reliable metrics that can pro-
vide information of the degree of autonomic modulation of the heart [47].
There are many factors that can directly or indirectly affect the autonomic nervous
system. In addition, any factors that change properties of the heart itself can also have
an effect on the heart rate [48]. Even though the direct effects of EP pulses used in
ECT on the autonomic nervous system were not expected, we performed HRV analysis
on the recorded signals to evaluate changes in the parameters of HRV induced by the
entire procedure, and to see if there were any changes not consistent with the known
effects of either post-surgical stress response or the drugs (especially anesthetics and
analgesics) used in postoperative treatment.
In our study, ECG signals recorded in the same night-time window when patients
were resting (from 0:00 to 4:00 a.m.) were chosen for evaluation of HRV before and
after ECT procedure in order to exclude the influence of circadian variation and
patient’s activity on HRV. Because HRV measures were compared for each patient
before and after ECT procedure (self-control), age and gender dependence of HRV was
minimized. None of the patients had clinically significant pre-existing cardiac condi-
tions (Table 1) - more detailed patient information can be found in Edhemovic et al.
[6]. As far as the ECT procedure was concerned, all patients received the same type of
treatment: the same type of anesthesia and analgesia were used during surgery; the
same type of surgical intervention was performed; similar duration of the procedure
(between 6 and 8 hours); ECT was performed with intravenously administered bleomy-
cin; and patients were exposed to similar pre- and post-operative care. HRV analysis
showed statistically significant change in median values of three HRV parameters
(Table 4). These effects could be attributed either to the effect of anesthesia, ECT
itself, post-operative drugs, and post-operative stress and pain response or to a combi-
nation of these factors.
Induction and maintenance of general anesthesia with sevoflurane and N2O are
known to cause a decrease in both the LF and HF components of the HRV power
spectra [49-54]. The degree of change tends to depend on the concentration of sevo-
flurane being used [51]. The recovery period of HRV after general anesthesia with
sevoflurane was reported to be short (from 30 to 180 minutes) [50,53,55]. The time
interval between the end of surgical procedure and the time period from which the
ECG record was taken for analysis was about 10 hours. It is therefore reasonable to
assume that the effects of inhalation anesthesia on HRV had been eliminated by then.
Delivery of EP pulses could also contribute to an increased heart rate but such
effects are reported to be only transient and were thus not expected to be present
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during the night-time after ECT procedure [56]. Interestingly, our results showed an
unexplained statistically significant negative correlation between changes in the LF
component of HRV and the number of EP pulses delivered to the patients (Table 5).
Epidural anesthesia decreases blood pressure and may be accompanied by a decrease
in heart rate. The principal mode of action of epidural blockade is prevention of sym-
pathetic outflow [57]. High thoracic epidural anesthesia (TEA) on level T1-T5 blocks
the cardiac afferent and efferent sympathetic fibers with loss of chronotropic and ino-
tropic drive to the myocardium [58]. In our patients epidural catheter was inserted at
T8-T12. TEA at this level has been shown to have several benefits, including improved
recovery after major abdominal surgery [59]. Epidural anesthesia restricted to the level
of the low thoracic and lumbar region (T5-L4) results in a peripheral sympathetic
blockade with vascular dilatation in the pelvis and lower limbs. Licker and his collea-
gues found that immediately after the operation with high TEA the total HRV and
both LF the HF components (as well as LF/HF ratio) were significantly decreased with
only the HF component returning to nearly pre-operation level within less than
24 hours [60]. Similarly, Jideus et al. found that the HRV variable expressing sympa-
thetic activity was significantly lower and that the postoperative increase in heart rate
was less pronounced in the high-TEA group than in the control group after surgery
[61]. In our study low TEA was used and thus we achieved splanchnic sympathetic
block, the intention was therefore not to influence cardiac sympathetic fibers directly.
However, some cranial spread of local anesthetic almost certainly occurred, especially
because we used low concentration of levobubivacaine with relative high volumes of
injectate. It has been found that low TEA (at T8/9) has indeed considerable cranial
spread and that this spread is even more extensive in the elderly and with higher
volumes of injectate [62]. In addition, our low TEA also resulted in sympathetic block
of adrenal catecholamine release. All this means that our observations of the decrease
in the LF component and lack of decrease in the HF component of HRV 10-12 hours
after the operation were consistent with the known effects of thoracic epidural
anesthesia and analgesia.
To avoid hypotension we used vassopresor norepinephrine at low infusion rates
(0.01 - 0.2 µg/kg/min) in postoperative care. Norepinephrine vascular effects in the
doses normally used clinically result from the simultaneous stimulation of alpha and
beta adrenergic receptors in the heart and vascular system. This results in an increase
in the force (and in the absence of vagal inhibition, in the rate) of myocardial contrac-
tion. Intravenous administration of norepinephrine results in intense vasoconstriction
and results in increase arterial pressure. The increase in blood pressure may cause a
reflex decrease in the heart rate [63,64]. Schächinger et al. found in their study on
healthy volunteers a significant decrease in the LF component of HRV (they did not
evaluate the HF component) and in the heart rate with norepinephrine infusion at
0.02-0.1 µg/kg/min [65]. Tulppo et al on the other hand found in their study on
healthy volunteers a significant increase in the HF component of HRV, no change in
LF component and a decrease in the heart rate with norepinephrine infusions at
0.05-0.15 µg/kg/min [66]. In our study the LF component of HRV was decreased,
which is in agreement with the results of Schächinger et al., but the heart rate was
increased. The decrease of the heart rate that could be expected as a reflex reaction to
norepinephrine infusion was most likely offset by the complex post-surgical stress
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response in our patients. In fact, tachycardia is one of many typical symptoms of the
stress response encountered in early postoperative intensive care [67].
According to the literature, analgesics given in post-operative care, especially opioids,
depress the LF component more than the HF component of the HRV spectrum, and
therefore reduce the LF/HF ratio, suggesting an increased parasympathetic dominance
in the HRV activity 529 [68]. Therefore, the observed significant decrease of LF and
nLF component (estimates of long-term HRV) after ECT procedure in our study were
most likely due to several analgesics (piritramide, sufentanil, metamizole) and local
anesthetics administered to patients in post-operative care.
Surgical pain and post-operative pain is known to trigger autonomic nervous and
endocrine responses, which can be manifested also as accelerated heart rate [56,69].
Consequently, shortened NN intervals and elevation of the LF component were
detected, but SDNN, HF, and total power of HRV were not found to be affected by
the pain [56,69,70]. In our study, statistically significant decrease in mean NN interval
after ECT procedure was detected but no elevation of the LF component was found,
therefore, the heart rate was probably not increased due to post-operative pain.
Conclusions
Intra-abdominal surgery involving ECT of colorectal liver metastases with synchronized
delivery of EP pulses does not present any life threat for the patient. Namely, no major
changes in functioning of the heart such as rhythm changes (i.e., increased induction
of abnormal heartbeats, ventricular tachycardia or fibrillation) or pathological morpho-
logical changes (e.g., changes in ST segment level) due to ECT procedure were found
in ECG signals recorded during early post-operative care. The probability for complica-
tions could increase when using EP pulses of longer durations or larger number of
pulses of increased pulse repetition frequency and/or in the treatment of tumors in the
immediate vicinity of the heart. Statistically significant although clinically irrelevant dif-
ferences in some HRV measures after ECT procedure were identified but they can be
explained by the known effects of post-operative drugs. In order to distinguish the
effects of ECT itself from those of post-operative drugs, the ECG recordings before
and after a similar surgical procedure but without ECT would be required, preferably
obtained from the same patients on which the ECT has been performed during a pre-
vious surgical procedure. However, cases where a surgical procedure involving intra-
abdominal ECT is followed by a similar surgical procedure without ECT are rare and
were not available for this study. In addition, for reliable investigation of influence of
different parameters of EP pulse delivery (such as number of delivered EP pulses, vol-
tage, current and energy), a detailed data about distance between location of EP pulse
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